NCT05694793

Brief Summary

The goal of this prospective trial is to assess the safety and reliability of the Glean Urodynamics System (GUS) in adult females with lower urinary tract symptoms. The main question\[s\] it aims to answer are: • What is GUS's ability to safely and reliably conduct wireless, catheter-free monitoring of vesical pressure compared to the vesical pressures collected with conventional urodynamics? Participants will undergo a conventional urodynamics exam, a simultaneous urodynamics exam with GUS, ambulatory urodynamics with GUS, and extended home monitoring with GUS. Researchers will compare GUS data with that from a conventional urodynamics exam.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
2mo left

Started Jun 2025

Geographic Reach
1 country

4 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Jun 2025Jul 2026

First Submitted

Initial submission to the registry

January 12, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 23, 2023

Completed
2.4 years until next milestone

Study Start

First participant enrolled

June 3, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

April 23, 2026

Status Verified

April 1, 2026

Enrollment Period

1.1 years

First QC Date

January 12, 2023

Last Update Submit

April 21, 2026

Conditions

Keywords

Lower Urinary Tract DysfunctionUrinary IncontinenceOveractive BladderHome MonitoringUrodynamicsUroflowmetry

Outcome Measures

Primary Outcomes (1)

  • Safety

    Proportion of participants experiencing a qualifying adverse event attributable to the investigational device

    From date of enrollment to study exit (up to 43 days)

Secondary Outcomes (1)

  • Vesical pressure

    during the procedure/surgery

Study Arms (1)

Glean Urodynamics System

EXPERIMENTAL
Device: Glean Urodynamics System

Interventions

Wireless, catheter-free urodynamics system

Also known as: GUS
Glean Urodynamics System

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female patient must be ≥ 18 years of age
  • Patient is a candidate for urodynamics per standard of care
  • Patient or patient's legally authorized representative is able to provide informed consent

You may not qualify if:

  • Pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months or intend to become pregnant during the study period
  • Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
  • Patient has history of recurrent UTIs (≥ 3 episodes in previous 12 months).
  • Patient has used antibiotics within the past 7 days from the baseline/screening visit.
  • Patient diagnosed with neurogenic LUTS (which may be associated with one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).
  • Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).
  • Patient with a urostomy.
  • Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall).
  • Patient who has from one or more major strictures in the urethra.
  • Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
  • Patient with a colostomy.
  • Patient with any abnormal or concerning rectal or vaginal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, active yeast infections, or vaginitis.
  • Patient has a known inability to void or is in complete retention.
  • Subjects who, at the principal investigator's determination, would not be appropriate for this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Tri Valley Urology Medical Group

Murrieta, California, 92562, United States

RECRUITING

University of California San Diego

San Diego, California, 92121, United States

COMPLETED

Unio Health Partners

Torrence, California, 90503, United States

WITHDRAWN

Cleveland Clinic

Cleveland, Ohio, 44195, United States

COMPLETED

Related Publications (1)

  • Frainey BT, Majerus SJA, Derisavifard S, Lewis KC, Williams AR, Balog BM, Butler RS, Goldman HB, Damaser MS. First in Human Subjects Testing of the UroMonitor: A Catheter-free Wireless Ambulatory Bladder Pressure Monitor. J Urol. 2023 Jul;210(1):186-195. doi: 10.1097/JU.0000000000003451. Epub 2023 Jun 9.

    PMID: 37293725BACKGROUND

MeSH Terms

Conditions

Urologic DiseasesUrinary IncontinenceUrinary Bladder, Overactive

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrination DisordersLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsUrinary Bladder Diseases

Central Study Contacts

Brittany Carter, DHSc

CONTACT

Suranjan Roychowdhury, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2023

First Posted

January 23, 2023

Study Start

June 3, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

April 23, 2026

Record last verified: 2026-04

Locations